<DOC>
	<DOCNO>NCT02422940</DOCNO>
	<brief_summary>This extension study evaluate long-term safety , tolerability , efficacy two dose strength dalfampridine-ER twice daily tablet administer least 12 month subject chronic post-ischemic stroke walk deficit complete controlled , double-blind Study DALF-PS-1016 .</brief_summary>
	<brief_title>An Extension Study Evaluate Long-Term Safety , Tolerability Efficacy Dalfampridine Extended-Release Tablets Treatment Chronic Post-Ischemic Stroke Walking Deficits Subjects Who Participated DALF-PS-1016 Study</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Key Completion DALFPS1016 study Providing inform consent continue DALFPS1029 longterm extension study Sufficient ambulatory ability independently complete Two Minute Walk Test ( 2MinWT ) 10 Meter Walk Test ( 10MWT ) time enrollment extension study Key Seizures , new onset stroke ( significant neurological event preclude longterm continuation ) occur antecedent DALFPS1016 study Calculated creatinine clearance â‰¤ 50 mL/minute time enrollment longterm extension study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>